# Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer

> **NCT00689624** · PHASE2 · COMPLETED · sponsor: **University Hospital of Crete** · enrollment: 30 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** Leukovorin
- **DRUG:** Oxaliplatin
- **DRUG:** 5-FLUOROURACIL
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT00689624
- **Lead sponsor:** University Hospital of Crete
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2015-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00689624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00689624, "Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00689624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*